Multi-modal Neuroimaging
To identify, compare and combine predictive markers of Alzheimer's disease, make a significant contribution to the understanding of the pathophysiological mechanisms of Alzheimer's disease, and study the ability of different neuroimaging techniques to follow the evolution of this pathology. (IMPA)
Young controls, middle age controls, elderly controls, autosomal dominant forms of early- onset AD, subjective cognitive impairment patients, mild cognitive impairment patients, AD patients, non-degenerative amnesic syndrome, frontotemporal lobe dementia (IMPA)
295 (IMPA)
Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage, blood draw, injection of PET dye, entering an fMRI machine (can induce claustrophobia), multiple in clinic visits
fMRI machine, PET scanner, dyes, cognitive tests, physican who can preform a lumbar puncture as well as a clinic designed for this testing, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)
University Hospital, Caen; Institut National de la Santé Et de la Recherche Médicale, France
- “Multi-modal Neuroimaging in Alzheimer's Disease (IMAP).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT01554202?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=4&rank=31
- “Multi-modal Neuroimaging in Alzheimer's Disease (IMAP+).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT01638949?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=2&rank=19